Combined analysis of the MF18-02/MF18-03 NEOSENTITURK studies: ypN-positive disease does not necessitate axillary lymph node dissection in patients with breast cancer with a good response to neoadjuvant chemotherapy as long as radiotherapy is provided.
axillary lymph node dissection
breast cancer
neoadjuvant chemotherapy
sentinel lymph node biopsy
targeted axillary dissection
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
30 Oct 2024
30 Oct 2024
Historique:
revised:
21
07
2024
received:
04
03
2024
accepted:
24
07
2024
medline:
30
10
2024
pubmed:
30
10
2024
entrez:
30
10
2024
Statut:
aheadofprint
Résumé
The omission of axillary lymph node dissection (ALND) remains controversial for patients with residual axillary disease after neoadjuvant chemotherapy (NAC), regardless of the residual burden. This study evaluated the oncologic safety and factors associated with outcomes in patients with residual axillary disease. These patients were treated solely with sentinel lymph node biopsy (SLNB) or targeted axillary dissection (TAD), without ALND, after NAC. A joint analysis of two different multicenter cohorts-the retrospective cohort registry MF18-02 and the prospective observational cohort registry MF18-03 (NCT04250129)-was conducted between January 2004 and August 2022. All patients received regional nodal irradiation. Five hundred and one patients with cT1-4, N1-3M0 disease who achieved a complete clinical response to NAC underwent either SLNB alone (n = 353) or TAD alone (n = 148). At a median follow-up of 42 months, axillary and locoregional recurrence rates were 0.4% (n = 2) and 0.8% (n = 4). No significant difference was found in disease-free survival (DFS) and disease-specific survival (DSS) rates between patients undergoing TAD alone versus SLNB alone, those with breast positive versus negative pathologic complete response, SLN methodology, total metastatic LN of one versus ≥2, or metastasis types as isolated tumor cells with micrometastases versus macrometastases. In the multivariate analysis, patients with nonluminal pathology were more likely to have a worse DFS and DSS, respectively, without an increased axillary recurrence. The omission of ALND can be safely considered for patients who achieve a complete clinical response after NAC, even if residual disease is detected by pathologic examination. Provided that adjuvant radiotherapy is administered, neither the SLNB method nor the number of excised LNs significantly affects oncologic outcomes.
Sections du résumé
BACKGROUND
BACKGROUND
The omission of axillary lymph node dissection (ALND) remains controversial for patients with residual axillary disease after neoadjuvant chemotherapy (NAC), regardless of the residual burden. This study evaluated the oncologic safety and factors associated with outcomes in patients with residual axillary disease. These patients were treated solely with sentinel lymph node biopsy (SLNB) or targeted axillary dissection (TAD), without ALND, after NAC.
METHODS
METHODS
A joint analysis of two different multicenter cohorts-the retrospective cohort registry MF18-02 and the prospective observational cohort registry MF18-03 (NCT04250129)-was conducted between January 2004 and August 2022. All patients received regional nodal irradiation.
RESULTS
RESULTS
Five hundred and one patients with cT1-4, N1-3M0 disease who achieved a complete clinical response to NAC underwent either SLNB alone (n = 353) or TAD alone (n = 148). At a median follow-up of 42 months, axillary and locoregional recurrence rates were 0.4% (n = 2) and 0.8% (n = 4). No significant difference was found in disease-free survival (DFS) and disease-specific survival (DSS) rates between patients undergoing TAD alone versus SLNB alone, those with breast positive versus negative pathologic complete response, SLN methodology, total metastatic LN of one versus ≥2, or metastasis types as isolated tumor cells with micrometastases versus macrometastases. In the multivariate analysis, patients with nonluminal pathology were more likely to have a worse DFS and DSS, respectively, without an increased axillary recurrence.
CONCLUSIONS
CONCLUSIONS
The omission of ALND can be safely considered for patients who achieve a complete clinical response after NAC, even if residual disease is detected by pathologic examination. Provided that adjuvant radiotherapy is administered, neither the SLNB method nor the number of excised LNs significantly affects oncologic outcomes.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.
Références
Giuliano AE, Ballman K, McCall L, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: long‐term follow‐up from the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 randomized trial. Ann Surg. 2016;264(3):413‐420. doi:10.1097/SLA.0000000000001863
Giuliano AE, Ballman KV, McCall L, et al. Effect of axillary dissection vs no axillary dissection on 10‐year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA. 2017;318(10):918‐926. doi:10.1001/jama.2017.11470
Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981‐22023 AMAROS): a randomized, multicentre, open‐label, phase 3 non‐inferiority trial. Lancet Oncol. 2014;15(12):1303‐1310. doi:10.1016/S1470‐2045(14)70460‐7
Bartels SAL, Donker M, Poncet C, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer: 10‐year results of the randomized controlled EORTC 10981‐22023 AMAROS trial. J Clin Oncol. 2023;41(12):2159‐2165.
Galimberti V, Cole BF, Viale G, et al. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel‐node micrometastases (IBCSG 23‐01): 10‐year follow‐up of a randomised, controlled phase 3 trial. Lancet Oncol. 2018;19(10):1385‐1393. doi:10.1016/S1470‐2045(18)30380‐2
Montagna G, Mamtani A, Knezevic A, Brogi E, Barrio AV, Morrow M. Selecting node‐positive patients for axillary downstaging with neoadjuvant chemotherapy. Ann Surg Oncol. 2020;27(27):4515‐4522. doi:10.1245/s10434‐020‐08650‐z
Nguyen TT, Hoskin TL, Day CN, et al. Decreasing use of axillary dissection in node‐positive breast cancer patients treated with neoadjuvant chemotherapy. Ann Surg Oncol. 2018;25(9):2596‐2602. doi:10.1245/s10434‐018‐6637‐9
Al‐Hilli Z, Hoskin TL, Day CN, Habermann EB, Boughey JC. Impact of neoadjuvant chemotherapy on nodal disease and nodal surgery by tumor subtype. Ann Surg Oncol. 2018;25(2):482‐493. doi:10.1245/s10434‐017‐6263‐y
Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node‐positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310(14):1455‐1461. doi:10.1001/jama.2013.278932
Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel‐lymph‐node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013;14(7):609‐618. doi:10.1016/S1470‐2045(13)70166‐9
Boileau JF, Poirier B, Basik M, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy‐proven node‐positive breast cancer: the SN FNAC study. J Clin Oncol. 2015;33(3):258‐264. doi:10.1200/JCO.2014.55.7827
Caudle AS, Yang WT, Krishnamurthy S, et al. Improved axillary evaluation following neoadjuvant therapy for patients with node‐positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol. 2016;34(10):1072‐1078.
Cabioglu N, Karanlık H, Kangal D, et al. Improved false negative rates with intraoperative identification of clipped nodes in patients undergoing sentinel lymph node biopsy after neoadjuvant chemotherapy. Ann Surg Oncol. 2018;25(10):3030‐3036. doi:10.1245/s10434‐018‐6575‐6
Tee SR, Devane LA, Evoy D, et al. Meta‐analysis of sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with initial biopsy‐proven node‐positive breast cancer. Br J Surg. 2018;105(12):1541‐1552. doi:10.1002/bjs.10986
Simons JM, van Nijnatten TJA, van der Pol CC, Luiten EJT, Koppert LB, Smidt ML. Diagnostic accuracy of different surgical procedures for axillary staging after neoadjuvant systemic therapy for node‐positive breast cancer: a systematic review and meta‐analysis. Ann Surg. 2019;269(3):432‐442. doi:10.1097/sla.0000000000003075
Kuemmel S, Heil J, Rueland A, et al. A prospective, multicenter registry study to evaluate the clinical feasibility of targeted axillary dissection (TAD) in node‐positive breast cancer patients. Ann Surg. 2022;276(5):e553‐e562. doi:10.1097/SLA.0000000000004572
Swarnkar PK, Tayeh S, Michell MJ, Mokbel, K. The evolving role of marked lymph node biopsy (MLNB) and targeted axillary dissection (TAD) after neoadjuvant chemotherapy (NACT) for node‐positive breast cancer: systematic review and pooled analysis. Cancers (Basel). 2021;13(7):1539. doi:10.3390/cancers13071539
A Randomized Phase III Clinical Trial Evaluation Post‐Mastectomy Chestwall and Regional Nodal XRT and Post‐Lumpectomy Regional Nodal XRT in Patients With Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy. NSABP B‐51/RTOG 1304 Trial, NCT01872975. http://meetinglibrary.asco.org/content/132077‐144
Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node‐Positive Breast Cancer Treated With Chemotherapy. Alliance for Clinical Trials in Oncology. A11202 Trial, NCT01872975. http://clinicaltrials.gov/ct2/show/NCT01901094
Gradishar WJ, Moran MS, Abraham J, et al. NCCN Guidelines® Insights: Breast Cancer, Version 4. J Natl Compr Canc Netw. 2023;21(6):594‐608. PMID: 37308117. doi: 10.6004/jnccn.2023.0031
Almahariq MF, Levitin R, Quinn TJ, et al. Omission of axillary lymph node dissection is associated with inferior survival in breast cancer patients with residual N1 nodal disease following neoadjuvant chemotherapy. Ann Surg Oncol. 2021;28(2):930‐940. doi:10.1245/s10434‐020‐08928‐2
Cabioglu N, Karanlık H, Yıldırım N, et al. Favorable outcome with sentinel lymph node biopsy alone after neoadjuvant chemotherapy in clinically node positive breast cancer at diagnosis: Turkish multicentric NEOSENTI‐TURK MF‐18‐02‐study. Eur J Surg Oncol. 2021;47(10):2506‐2514. doi:10.1016/j.ejso.2021.06.024
van Loevezijn AA, vander Noordaa MEM, Stokkel MPM, et al. Three‐year follow‐up of de‐escalated axillary treatment after neoadjuvant systemic therapy in clinically node‐positive breast cancer: the MARI‐protocol. Breast Cancer Res Treat. 2022;193(1):37‐48. doi:10.1007/s10549‐022‐06545‐z
Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy (NEOSENTITURK). Federation of Breast Diseases Societies, Trial NCT04250129. http://clinicaltrials.gov/ct2/show/NCT04250129
American Joint Committee on Cancer Staging Manual. Part IX: Breast. 8th ed. American College of Surgeons; 2018.
Simsek DH, Emiroglu S, Yilmaz R, et al. SPECT/CT lymphoscintigraphy guidance simplifies and improves targeted axillary dissection of the clipped nodes after neoadjuvant chemotherapy in initially node‐positive breast cancer. Clin Nucl Med. 2022;47(11):e682‐e688. doi:10.1097/RLU.0000000000004340
Dilege E, Celik B, Falay O, et al. SPECT/CT lymphoscintigraphy accurately localizes clipped and sentinel nodes after neoadjuvant chemotherapy in node‐positive breast cancer. Clin Nucl Med. 2023;48(7):594‐599. doi:10.1097/RLU.0000000000004669
Ozkurt E, Yardımcı E, Tükenmez M, et al. Intraoperative palpation of sentinel lymph nodes can accurately predict axilla in early breast cancer. Breast J. 2019;25(1):96‐102. doi:10.1111/tbj.13149
Ozmen V, Unal ES, Muslumanoglu ME, et al. Axillary sentinel node biopsy after neoadjuvant chemotherapy. Eur J Surg Oncol. 2010;36(1):23‐29. doi:10.1016/j.ejso.2009.10.015
Mazouni C, Peintinger F, Wan‐Kau S, et al. Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. J Clin Oncol. 2007;25(19):2650‐2655. doi:10.1200/jco.2006.08.2271
Untch M, Gerber B, Harbeck N, et al. 13th St. Gallen International Breast Cancer Conference 2013: primary therapy of early breast cancer evidence, controversies, consensus—opinion of a German team of experts (Zurich 2013). Breast Care (Basel). 2013;8(3):221‐229.
Hersh EH, King TA. De‐escalating axillary surgery in early‐stage breast cancer. Breast. 2022;62(suppl 1):S43‐S49. doi:10.1016/j.breast.2021.11.018
Kahler‐Ribeiro‐Fontana S, Pagan E, Magnoni F, et al. Long‐term standard sentinel node biopsy after neoadjuvant treatment in breast cancer: a single institution ten‐year follow‐up. Eur J Surg Oncol. 2021;47(4):804‐812. doi:10.1016/j.ejso.2020.10.014
Barrio AV, Montagna G, Mamtani A, et al. Nodal recurrence in patients with node‐positive breast cancer treated with sentinel node biopsy alone after neoadjuvant chemotherapy—a rare event. JAMA Oncol. 2021;7(12):1851‐1855. doi:10.1001/jamaoncol.2021.4394
Montagna G, Mrdutt MM, Sun SX, et al. Omission of axillary dissection following nodal downstaging with neoadjuvant chemotherapy. JAMA Oncol. 2024;10(6):793‐798. doi:10.1001/jamaoncol.2024.0578
van Nijnatten TJ, Simons JM, Moossdorff M, et al. Prognosis of residual axillary disease after neoadjuvant chemotherapy in clinically node‐positive breast cancer patients: isolated tumor cells and micrometastases carry a better prognosis than macrometastases. Breast Cancer Res Treat. 2017;163(1):159‐166. doi:10.1007/s10549‐017‐4157‐0
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15‐year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687‐1717. doi:10.1016/S0140‐6736(05)66544‐0
Banys‐Paluchowski M, Gasparri ML, de Boniface J, et al. Surgical management of the axilla in clinically node‐positive breast cancer patients converting to clinical node negativity through neoadjuvant chemotherapy: current status, knowledge gaps, and rationale for the EUBREAST‐03 AXSANA study. Cancers (Basel). 2021;13(7):1565.
Henke G, Kanuer M, Ribi K, et al. Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node‐positive breast cancer (TAXIS): study protocol for a multicenter, randomised phase‐III trial. Trials. 2018;19:667.